Search for: "Actavis"
Results 821 - 840
of 1,010
Sorted by Relevance
|
Sort by Date
11 Jan 2011, 11:07 pm
Senators follow House colleagues in making BPCIA exclusivity clarifications; New study suggests benefits of longer drug exclusivity period (FDA Law Blog) US: BPCIA’s principal authors seek to clarify Congressional intent with respect to 12-year exclusivity period; PhRMA/BIO request ‘umbrella exclusivity’ (FDA Law Blog) US: BIO’s IP priorities for 2011 (PatentlyBIOtech) US: BIO survey shows support for DNA-based patents despite some reservations (Patent Docs) US:… [read post]
30 Jul 2009, 11:32 am
v=dum81RdFrhM&feature=player_embedded Unfortunately, both the manufacturer of Reglan (Wyeth Pharmaceuticals) and manufacturers of the generic metoclopramide (Actavis Elizabeth, Teva Pharmaceuticals USA, Pliva and Barr Pharmaceuticals) have placed profits before patient safety. [read post]
19 Dec 2008, 1:00 pm
$16.8 million for Alphapharm and Mylan: Takeda v Mylan (Patent Baristas) (Patent Docs) Boniva (Ibandronic acid) – US: Apotex challenges validity of Hoffmann-La Roche’s Boniva patent (Law360) Boniva (Ibandronic acid) – US: Orchid Chemicals & Pharmaceuticals and Orgenus Pharma seek declaratory judgment of invalidity and noninfringement in patent infringement suit brought by Hoffmann-La Roche over Boniva (Law360) Cardizem (Diltiazem) – Antitrust,… [read post]
6 Apr 2018, 3:42 am
Interestingly, in light of the Supreme Court decision in Actavis v Lilly having been handed down after the first instance judgment in the present proceedings, Regeneron appears to have argued that even if Kymab was right on construction, there was still infringement under the newly-conceived English law doctrine of equivalents. [read post]
10 Jun 2010, 3:58 am
Actavis Inc. et al. [read post]
5 Feb 2019, 1:19 am
Based on the Pemetrexed-decision of the German Federal Supreme Court (docket-no X ZR 29/15, also known as Actavis v Eli Lilly), the Court of Appeal made it clear that Swiss-type claims are to be treated in the same way as so-called EPC 2000-claims. [read post]
6 Jul 2010, 6:03 pm
(Patent Docs) (Holman’s Biotech IP Blog) US: AMP v USPTO after Bilski v Kappos (Patent Docs) US: NORD Chair/HP&M Director presents opening testimony at first ever FDA orphan drug hearing (FDA Law Blog) US: Celsis files patent infringement complaint against CellzDirect and Invitrogen over pooled multi-cryopreserved hepatocyte products (Patent Docs) Products Astelin (Azelastine) – US: Zydus admits infringing Meda’s Astelin patent, agrees not to market generic (Patent Docs)… [read post]
17 Feb 2010, 2:02 pm
This particular Kat was busy digesting the Court of Appeal's decision in Actavis v Novartis when another part of the IPKat commented on it here. [read post]
5 Jun 2020, 7:00 am
The petitions of the week are below the jump: Actavis Holdco U.S. [read post]
31 May 2011, 8:38 pm
Novo Nordisk (Orange Book Blog) Silenor (Doxepin) – US: Somaxon files patent infringement lawsuit against Par Pharmaceuticals over bid to market generic Silenor (GenericsWeb) Strattera (Atomoxetine) – US: Eli Lilly files patent infringement complaint against Zydus in response to Para IV certification (Patent Docs) Zemplar (Paricalcitol) – US: Abbott Lab’s files patent infringement complaint against Sandoz in response to Para IV certification (Patent Docs) Ziana (Clindamycin,… [read post]
18 Feb 2019, 1:00 am
Actavis Group PTC EHF & Ors v ICOS Corporation & Anor, heard 19-20 Nov 2018. [read post]
28 Sep 2011, 1:56 am
(Kluwer Patent Blog) Gabitril (Tiagabine) – US: Cephalon files suits against Sun Pharma. in New Jersey and Michigan in response to Para IV certification (Patent Docs) Glivec (Imatinib) – India: Novartis Glivec patent case: preliminary objection (Spicy IP) Lovenox (Enoxaparin) – US: Momenta files patent infringement complaint against Amphastar in response to impending launch of generic Lovenox (Patent Docs) Lumigan (Bimatoprost) – US: Validity of Allergan Lumigan patents… [read post]
5 Dec 2010, 3:02 pm
Next was Mr Justice Floyd, who considered the validity of intent-based claims – claims for products distinguished by the purpose or intent for which they are used, as discussed in Adhesive Dry Mounting (Ch 1910), Actavis v Merck (CA 2008) and Mobil/friction reducing additive (EBA 1989) – and the impact of claim categories on the inherent patentability of products more generally. [read post]
9 Mar 2011, 3:00 am
Allergan, Inc (Chicago IP Litigation Blog) Synagis (Palivizumab) – US: PDL BioPharma settles Medimmune Synagis litigation for $93M (Patent Docs) TriCor (Fenofibrate) – US: Abbott and Elan end TriCor suit with Ranbaxy (Patent Docs) Valsartan – Norway: Oslo District Court holds Actavis’ Valsartan/HCTZ product infringes Novartis’ patent covering synthesis route for Valsartan; deals inter alia with scope of Valsartan SPC (The SPC Blog) [read post]
19 Nov 2018, 1:00 am
On Monday 19 and Tuesday 20 November, the Supreme Court will hear the appeal of Actavis Group PTC EHF & Ors v ICOS Corporation & Anor. [read post]
26 Nov 2018, 2:09 am
In addition, although the question answered by the CJEU dealt with article 3 (a), its legal grounds may also be applied to interpret article 3 (c), as shown by the judgment of 12 March 2015 (Case C-577/13 Actavis v. [read post]
4 Feb 2019, 1:00 am
Actavis Group PTC EHF & Ors v ICOS Corporation & Anor, heard 19-20 Nov 2018. [read post]
13 Jan 2010, 3:00 am
Actavis Elizabeth LLC (Docket Report) US: Inclusion of Pay-for-Delay ban in Health Care Bill urged; FTC to hold press conference announcing pay-for-delay analysis (FDA Law Blog) US: Drug molecules going off patent in 2010 (Patentcircle) Products Cipramil (Citalopram) - EU: Commission opens antitrust investigation into pharmaceutical company Lundbeck (EPLAW) (Managing IP) (GenericsWeb) Hectorol (Doxercalciferol) - US: Genzyme files patent infringement complaint against Cobrek in N D… [read post]
6 Dec 2018, 12:31 pm
Actavis, 570 U.S. 136 (2013), parties entering into trademark settlements are not immune from antitrust liability. [read post]
21 Jan 2019, 1:00 am
Actavis Group PTC EHF & Ors v ICOS Corporation & Anor, heard 19-20 Nov 2018. [read post]
